Hemoglobin measuring reagent and hemoglobin measuring method

A reagent using nonionic or amphoteric surfactants addresses the REACH restrictions on polyoxyethylene octylphenyl ether by ensuring effective hemolysis and high accuracy in hemoglobin measurements, maintaining peak stability and reducing carryover.

JP7593713B2Active Publication Date: 2024-12-03SEKISUI MEDICAL CO LTD
View PDF 24 Cites 0 Cited by

Patent Information

Application Number
JP2023137862
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2018-09-12
Filing Date
2023-08-28
Publication Date
2024-12-03
Estimated Expiration
2039-09-05

AI Technical Summary

Technical Problem

The use of polyoxyethylene octylphenyl ether with an average number of added moles of oxyethylene groups of 10 in hemolytic reagents is restricted by REACH regulations, necessitating the development of a reagent that can achieve equivalent hemolysis and accuracy in measuring hemoglobins without this component.

Method used

A reagent for measuring hemoglobins using nonionic or amphoteric surfactants, such as polyoxyethylene alkyl ethers and amphoteric surfactants like 3-[(3-cholamidopropyl)dimethylammonio]propanesulfonate, which can cause effective hemolysis and maintain high accuracy in hemoglobin measurements.

Benefits of technology

The reagent achieves high accuracy in hemoglobin measurements with reduced environmental impact by avoiding restricted chemicals, ensuring stable peak shapes and reducing carryover, even with prolonged sample storage and continuous measurements.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007593713000009
    Figure 0007593713000009
  • Figure 0007593713000010
    Figure 0007593713000010
  • Figure 0007593713000011
    Figure 0007593713000011
Patent Text Reader

Abstract

To provide hemoglobin measurement reagents which can hemolyze blood well and enable highly accurate measurement of hemoglobins.SOLUTION: Hemoglobin measurement reagents of the present invention are used for measuring hemoglobins by means of cationic exchange liquid chromatography, and contain a specific nonionic surfactant or specific amphoteric surfactant.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a reagent for measuring hemoglobins, which contains a surfactant. The present invention also relates to a method for measuring hemoglobins using the reagent for measuring hemoglobins. [Background technology]

[0002] Conventionally, the concentration of hemoglobins has been measured for the diagnosis of diabetes and abnormal hemoglobin diseases. For example, the concentrations of hemoglobins such as hemoglobin A1a, hemoglobin A1b, hemoglobin F, hemoglobin A1c, hemoglobin A0 and hemoglobin A2, modified hemoglobins such as acetylated hemoglobin and carbamylated hemoglobin, and abnormal hemoglobins such as hemoglobin S and hemoglobin C have been measured. Among these hemoglobins, the hemoglobin A1c value has been measured in particular. The method for measuring the concentration of hemoglobins mainly includes liquid chromatography.

[0003] In the liquid chromatography method, a hemolysis reagent is added to a specimen such as blood, the hemolyzed sample is measured by cation exchange liquid chromatography, and the peaks of the obtained chromatogram are processed to determine the concentration of hemoglobins such as the hemoglobin A1c value. Conventionally, a composition containing polyoxyethylene octylphenyl ether (e.g., product name "Triton X-100") with an average added mole number of oxyethylene groups of 10 has been used as the hemolysis reagent.

[0004] The following Patent Document 1 discloses a method for separating hemoglobin A1c in a human blood sample from other glycosylated and non-glycosylated hemoglobin and Schiff bases of precursors of hemoglobin A1c. In addition, in the examples of Patent Document 1, a hemolysis reagent containing 0.33% by weight of Triton X-100 is used.

[0005] The following Patent Document 2 discloses a hemolytic reagent used for hemolyzing a blood sample in a method for measuring hemoglobin by cation exchange liquid chromatography. The hemolytic reagent contains chaotropic ions. In addition, in the examples of Patent Document 2, a hemolytic reagent containing 0.1% by weight of Triton X-100 is used. [Prior art documents] [Patent documents]

[0006] [Patent Document 1] Japanese Patent Application Publication No. 58-191968 [Patent Document 2] JP 2001-021555 A Summary of the Invention [Problem to be solved by the invention]

[0007] A hemolytic reagent (hemoglobin measuring reagent) containing polyoxyethylene octylphenyl ether having an average added mole number of oxyethylene groups of 10 as described in Patent Documents 1 and 2 has excellent hemolytic performance. Therefore, when a sample such as whole blood is treated with the hemolytic reagent and measured by cation exchange liquid chromatography, a good peak of hemoglobins is obtained. Furthermore, shoulder peaks and peak splitting are unlikely to occur in all the obtained peaks. Therefore, hemoglobins can be measured with high accuracy.

[0008] In addition, a hemolysis reagent containing polyoxyethylene octylphenyl ether, the average number of moles of oxyethylene groups added of which is 10, has low carryover when measured by cation exchange liquid chromatography. Therefore, hemoglobin can be measured with high accuracy even when many samples are measured continuously.

[0009] Meanwhile, in Europe, the REACH regulation (Registration, Evaluation, Authorisation and Restriction of Chemicals) came into effect in 2007, restricting the use of certain chemicals. In addition, in 2017, products containing 0.1% by weight or more of polyoxyethylene octylphenyl ether, which has an average number of added moles of oxyethylene groups of 10, became subject to the REACH regulation. Furthermore, reducing the amount of use of polyoxyethylene octylphenyl ether, which has an average number of added moles of oxyethylene groups of 10, in countries outside of Europe will also contribute to reducing the environmental burden and improving safety for the human body.

[0010] The object of the present invention is to provide a hemoglobin measuring reagent capable of causing good hemolysis and measuring hemoglobin with high accuracy. More specifically, the object of the present invention is to provide a hemoglobin measuring reagent that, even if it does not contain polyoxyethylene octylphenyl ether having an average added mole number of oxyethylene groups of 10, can cause hemolysis at the same level as a hemoglobin measuring reagent containing said component and can measure hemoglobin with the same accuracy.

[0011] Another object of the present invention is to provide a method for measuring hemoglobins using the above-mentioned reagent for measuring hemoglobins. [Means for solving the problem]

[0012] According to a broad aspect of the present invention, there is provided a reagent for measuring hemoglobins, which is used for measuring hemoglobins by cation exchange liquid chromatography, the reagent comprising a nonionic surfactant or an amphoteric surfactant, wherein the nonionic surfactant is component A1, component A2, component A3, component A4, component A5, component A6, component A7, component A8, or component A9, and the amphoteric surfactant is component B1, component B2, or component B3.

[0013] Component A1: A polyoxyethylene alkyl ether having an average added mole number of oxyethylene groups of 8 or more and 20 or less and an alkyl group having a carbon number of 12 or more and 17 or less.

[0014] Component A2: Polyoxyethylene stearyl ether having an average added mole number of oxyethylene groups of 40 or more and 60 or less.

[0015] Component A3: Polyoxyethylene oleyl ether having an average added mole number of oxyethylene groups of 9 to 15

[0016] Component A4: A polyoxyethylene-sec-alkyl ether having an average added mole number of oxyethylene groups of 6 or more and 10 or less, and an alkyl group having a carbon number of 11 or more and 15 or less.

[0017] Component A5: Polyoxyethylene tridecyl ether having an average added mole number of oxyethylene groups of 15

[0018] Ingredient A6: Polyoxyethylene polyoxypropylene alkyl ether having an HLB value of 11 or more and 15 or less

[0019] Ingredient A7: n-nonanoyl-N-methyl-D-glucamine

[0020] Ingredient A8: n-Octyl-β-D-glucopyranoside

[0021] Ingredient A9: Saponin

[0022] Component B1: 3-[(3-cholamidopropyl)dimethylammonio]propanesulfonate

[0023] Component B2: 3-[(3-cholamidopropyl)dimethylammonio]-2-hydroxypropanesulfonate

[0024] Ingredient B3: Lauryl dimethylamine oxide

[0025] In a specific aspect of the reagent for measuring hemoglobins according to the present invention, the nonionic surfactant is contained, and the nonionic surfactant contains the component A1, the component A2, the component A3, the component A4, the component A5, or the component A6, the component A1 is polyoxyethylene lauryl ether having an average number of moles of oxyethylene groups added of 9, 12, or 19, or polyoxyethylene cetyl ether having an average number of moles of oxyethylene groups added of 13 or 20, the component A2 is polyoxyethylene stearyl ether having an average number of moles of oxyethylene groups added of 50, the component A3 is polyoxyethylene oleyl ether having an average number of moles of oxyethylene groups added of 9 or 13, the component A4 is polyoxyethylene-sec-alkyl ether having an average number of moles of oxyethylene groups added of 7 or 9 and having an alkyl group with a carbon number of 11 to 15, and the component A6 is polyoxyethylene polyoxypropylene alkyl ether having an HLB value of 12.5, 12.7, or 14.0.

[0026] In a specific aspect of the reagent for measuring hemoglobins according to the present invention, the reagent contains the nonionic surfactant, and the nonionic surfactant contains the component A1 or the component A3, the component A1 is a polyoxyethylene alkyl ether having an average number of moles of oxyethylene groups added of 10 or more and 15 or less and having 12 or more and 17 or less carbon atoms in the alkyl group, and the component A3 is a polyoxyethylene oleyl ether having an average number of moles of oxyethylene groups added of 10 or more and 15 or less.

[0027] In a specific aspect of the reagent for measuring hemoglobins according to the present invention, the component A1 is polyoxyethylene lauryl ether having an average number of moles of oxyethylene groups added of 12, or polyoxyethylene cetyl ether having an average number of moles of oxyethylene groups added of 13, and the component A3 is polyoxyethylene oleyl ether having an average number of moles of oxyethylene groups added of 13.

[0028] In a specific aspect of the reagent for measuring hemoglobins according to the present invention, the reagent contains the nonionic surfactant, and the content of the nonionic surfactant is 0.01% by weight or more and 1.0% by weight or less.

[0029] In a specific aspect of the reagent for measuring hemoglobins according to the present invention, the reagent contains the amphoteric surfactant, and the content of the amphoteric surfactant is 0.01% by weight or more and 1.0% by weight or less.

[0030] According to a broad aspect of the present invention, there is provided a method for measuring hemoglobins, comprising the steps of: mixing a red blood cell-containing sample with the above-mentioned hemoglobin measuring reagent to obtain a mixed solution; and measuring the mixed solution by cation exchange liquid chromatography. Effect of the Invention

[0031] The hemoglobin measuring reagent according to the present invention is used for measuring hemoglobins by cation exchange liquid chromatography. The hemoglobin measuring reagent according to the present invention contains a nonionic surfactant or an amphoteric surfactant. In the hemoglobin measuring reagent according to the present invention, the nonionic surfactant is any one of the following components A1 to A9, or the amphoteric surfactant is any one of the following components B1 to B3. Component A1: a polyoxyethylene alkyl ether having an average number of moles of oxyethylene groups added of 8 to 20 and having an alkyl group with 12 to 17 carbon atoms. Component A2: a polyoxyethylene stearyl ether having an average number of moles of oxyethylene groups added of 40 to 60. Component A3: a polyoxyethylene oleyl ether having an average number of moles of oxyethylene groups added of 9 to 15. Component A4: a polyoxyethylene-sec-alkyl ether having an average number of moles of oxyethylene groups added of 6 to 10 and having an alkyl group with 11 to 15 carbon atoms. Component A5: polyoxyethylene tridecyl ether having an average number of moles of oxyethylene groups added of 15. Component A6: polyoxyethylene polyoxypropylene alkyl ether having an HLB value of 11 or more and 15 or less. Component A7: n-nonanoyl-N-methyl-D-glucamine. Component A8: n-octyl-β-D-glucopyranoside. Component A9: saponin. Component B1: 3-[(3-cholamidopropyl)dimethylammonio]propanesulfonate. Component B2: 3-[(3-cholamidopropyl)dimethylammonio]-2-hydroxypropanesulfonate. Component B3: lauryldimethylamine oxide. The hemoglobin measuring reagent according to the present invention has the above-mentioned configuration, and therefore can perform good hemolysis and can measure hemoglobin with high accuracy. [Brief description of the drawings]

[0032] [Figure 1] FIG. 1 is an example of a chromatogram obtained when measurement is performed by cation exchange liquid chromatography using a hemoglobin measuring reagent according to one embodiment of the present invention. [Diagram 2]FIG. 2 shows an example of a chromatogram obtained when a conventional hemoglobin measuring reagent is used for measurement by cation exchange liquid chromatography. [Diagram 3] 3(a) and (b) are examples of chromatograms evaluating the shape of the hemoglobin A0 peak. [Figure 4] 4(a) and (b) are examples of chromatograms evaluating the peak shape of the first fraction. [Diagram 5] 5(a) to (c) are examples of chromatograms in which the hemoglobin A0 peak height is evaluated. [Figure 6] 6(a) and (b) are diagrams showing the relationship between the number of days of storage and the hemoglobin A1c value and the amount of change in the hemoglobin A1c value in a mixture of a hemoglobin measuring reagent and whole blood. [Figure 7] 7(a) and (b) are diagrams showing the relationship between the number of days of storage and the hemoglobin A1c value and the amount of change in the hemoglobin A1c value for a mixture of a hemoglobin measurement reagent and a hemoglobin A1c substance (low concentration) (IRC-L) for measurement control. [Figure 8] 8(a) and (b) are diagrams showing the relationship between the number of days of storage and the hemoglobin A1c value and the amount of change in the hemoglobin A1c value for a mixture of a hemoglobin measurement reagent and a measurement control hemoglobin A1c substance (high concentration) (IRC-H). [Figure 9] 9(a) and (b) are diagrams showing column durability in a mixed solution of a hemoglobin measuring reagent and a measurement control hemoglobin A1c substance (high concentration) (IRC-H). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0033] The present invention will be described in detail below.

[0034] The reagent for measuring hemoglobins according to the present invention is used for measuring hemoglobins by cation exchange liquid chromatography. The reagent for measuring hemoglobins according to the present invention contains a nonionic surfactant or an amphoteric surfactant.

[0035] In the hemoglobin measuring reagent according to the present invention, the nonionic surfactant is a polyoxyethylene alkyl ether having an average number of added moles of oxyethylene groups of 8 or more and 20 or less and the alkyl group has a carbon number of 12 or more and 17 or less, a polyoxyethylene stearyl ether having an average number of added moles of oxyethylene groups of 40 or more and 60 or less, a polyoxyethylene oleyl ether having an average number of added moles of oxyethylene groups of 9 or more and 15 or less, a polyoxyethylene-sec-alkyl ether having an average number of added moles of oxyethylene groups of 6 or more and 10 or less and the alkyl group has a carbon number of 11 or more and 15 or less, a polyoxyethylene tridecyl ether having an average number of added moles of oxyethylene groups of 15, a polyoxyethylene polyoxypropylene alkyl ether having an HLB value of 11 or more and 15 or less, n-nonanoyl-N-methyl-D-glucamine, n-octyl-β-D-glucopyranoside, or saponin.

[0036] In the reagent for measuring hemoglobins according to the present invention, the amphoteric surfactant is 3-[(3-cholamidopropyl)dimethylammonio]propanesulfonate, 3-[(3-cholamidopropyl)dimethylammonio]-2-hydroxypropanesulfonate, or lauryldimethylamine oxide.

[0037] In this specification, "a polyoxyethylene alkyl ether having an average added mole number of oxyethylene groups of 8 or more and 20 or less, and an alkyl group having 12 or more and 17 or less carbon atoms" may be referred to as "component A1".

[0038] Of component A1, “a polyoxyethylene alkyl ether having an average added mole number of oxyethylene groups of 10 or more and 15 or less, and an alkyl group having 12 or more and 17 or less carbon atoms” may be referred to as “component A1′” in this specification.

[0039] In this specification, "polyoxyethylene stearyl ether having an average number of moles of oxyethylene groups added of 40 or more and 60 or less" may be referred to as "component A2".

[0040] In this specification, "polyoxyethylene oleyl ether having an average number of moles of oxyethylene groups added of 9 or more and 15 or less" may be referred to as "component A3".

[0041] Of component A3, "polyoxyethylene oleyl ether having an average number of moles of oxyethylene groups added of 10 or more and 15 or less" may be referred to as "component A3'" in this specification.

[0042] In this specification, "a polyoxyethylene-sec-alkyl ether having an average added mole number of oxyethylene groups of 6 or more and 10 or less, and an alkyl group having 11 or more and 15 or less carbon atoms" is sometimes referred to as "component A4".

[0043] In this specification, "polyoxyethylene tridecyl ether having an average added mole number of oxyethylene groups of 15" may be referred to as "component A5."

[0044] In this specification, "polyoxyethylene polyoxypropylene alkyl ether having an HLB value of 11 or more and 15 or less" may be referred to as "component A6."

[0045] In this specification, "n-nonanoyl-N-methyl-D-glucamine" may be referred to as "ingredient A7."

[0046] In this specification, "n-octyl-β-D-glucopyranoside" may be referred to as "ingredient A8."

[0047] In this specification, "saponin" may be referred to as "component A9."

[0048] In this specification, "3-[(3-cholamidopropyl)dimethylammonio]propanesulfonate" may be referred to as "ingredient B1."

[0049] In this specification, "3-[(3-cholamidopropyl)dimethylammonio]-2-hydroxypropanesulfonate" may be referred to as "component B2".

[0050] In this specification, "lauryl dimethylamine oxide" may be referred to as "ingredient B3."

[0051] In this specification, "polyoxyethylene octylphenyl ether having an average added mole number of oxyethylene groups of 10" may be referred to as "component X."

[0052] The hemoglobin measuring reagent according to the present invention contains a nonionic surfactant or an amphoteric surfactant, and the nonionic surfactant is component A1, component A2, component A3, component A4, component A5, component A6, component A7, component A8 or component A9, or the amphoteric surfactant is component B1, component B2 or component B3.

[0053] Since the reagent for measuring hemoglobin according to the present invention has the above-mentioned configuration, it can perform hemolysis well and can measure hemoglobin with high accuracy.

[0054] A conventional hemoglobin measuring reagent containing component X can achieve good hemolysis and can measure hemoglobin with high accuracy. On the other hand, it is difficult to achieve good hemolysis and measure hemoglobin with high accuracy using a hemoglobin measuring reagent not containing component X.

[0055] In contrast, since the hemoglobin measuring reagent according to the present invention has the above-mentioned configuration, even when it does not contain component X, it can cause hemolysis at the same level as a hemoglobin measuring reagent containing component X, and can measure hemoglobin with the same accuracy.

[0056] The hemoglobin measuring reagent according to the present invention can achieve good hemolysis, and therefore can obtain good peaks of hemoglobin when measured by cation exchange liquid chromatography. Furthermore, shoulder peaks and peak splitting are unlikely to occur in all peaks obtained. Therefore, hemoglobin can be measured with high accuracy. Furthermore, the hemoglobin measuring reagent according to the present invention can reduce carryover. Therefore, hemoglobin can be measured with high accuracy even when a large number of samples are measured continuously.

[0057] In addition, in the testing center, after mixing the hemolysis reagent (hemoglobin measuring reagent) with the test substance, the mixture may be stored for a certain period (e.g., several days) before being measured by cation exchange chromatography. The hemoglobin measuring reagent according to the present invention can improve the storage stability of the mixture in which the reagent and the test substance are mixed. The test substance includes not only red blood cell-containing specimens such as blood (e.g., blood of a test subject), but also hemoglobin-containing specimens not containing red blood cells (e.g., hemoglobin standard substances and hemoglobin substances for measurement control, etc.). In the hemoglobin measuring reagent according to the present invention, even if the mixture is stored for a certain period, the peak shape of hemoglobin is unlikely to change before and after storage, and the measured value is unlikely to fluctuate.

[0058] In particular, when the hemoglobin measuring reagent of the present invention contains component A1' or component A3', the storage stability of the mixed liquid in which the hemoglobin measuring reagent and the test substance are mixed can be further improved, and the storage stability of the hemoglobin measuring reagent can also be improved.

[0059] The hemoglobin measuring reagent according to the present invention is used for measuring hemoglobin by cation exchange liquid chromatography. The above-mentioned hemoglobin measuring reagent is preferably used for measuring hemoglobin by cation exchange high performance liquid chromatography.

[0060] Examples of the hemoglobins include hemoglobins such as hemoglobin A1a, hemoglobin A1b, hemoglobin F, hemoglobin A1c, hemoglobin A0, and hemoglobin A2; modified hemoglobins such as acetylated hemoglobin and carbamylated hemoglobin; and abnormal hemoglobins such as hemoglobin S and hemoglobin C.

[0061] The reagent for measuring hemoglobin according to the present invention is suitably used for measuring the above-mentioned hemoglobin A1c value (hemoglobin A1c concentration).

[0062] FIG. 1 is an example of a chromatogram obtained when measurement is performed by cation exchange liquid chromatography using a hemoglobin measuring reagent according to one embodiment of the present invention.

[0063] FIG. 2 is an example of a chromatogram obtained when a conventional hemoglobin measuring reagent (a conventional hemoglobin measuring reagent containing component X) is used for measurement by cation exchange liquid chromatography.

[0064] In Figures 1 and 2, the peak detected at about 19 seconds is the peak of hemoglobin A1c, and the peak detected at about 40 seconds is the peak of hemoglobin A0. Figures 1 and 2 are examples of chromatograms measured under the measurement conditions in the examples described later.

[0065] With the reagent for measuring hemoglobins according to the present invention, a peak shape equivalent to that of a conventional reagent for measuring hemoglobins containing component X can be obtained.

[0066] The hemoglobin measuring reagent according to the present invention does not contain any component subject to REACH regulation, and therefore has a smaller impact on the environment and is safer than conventional hemoglobin measuring reagents that contain component X.

[0067] The reagent for measuring hemoglobins according to the present invention may contain the nonionic surfactant, may contain the amphoteric surfactant, or may contain both the nonionic surfactant and the amphoteric surfactant.

[0068] (Nonionic surfactant) The hemoglobin measuring reagent preferably contains a nonionic surfactant. The nonionic surfactant is any one of components A1 to A9. The nonionic surfactant may be one of components A1 to A9, or two or more of the components A1 to A9 may be used in combination.

[0069] <Ingredient A1> Component A1 is a polyoxyethylene alkyl ether in which the average number of moles of oxyethylene groups added is 8 to 20 and the number of carbon atoms in the alkyl group is 12 to 17. Component A1 is a component represented by the following formula (1). Only one type of component A1 may be used, or two or more types may be used in combination.

[0070] RO(CH2CH2O) n H (1)

[0071] In the above formula (1), R represents an alkyl group having 12 to 17 carbon atoms, and n represents a number of 8 to 20.

[0072] In polyoxyethylene alkyl ethers in which the average number of moles of oxyethylene groups added is less than 8 and the number of carbon atoms in the alkyl group is less than 12, the surfactant is difficult to dissolve, and a hemoglobin measuring reagent may not be prepared. In addition, in polyoxyethylene alkyl ethers in which the average number of moles of oxyethylene groups added is less than 8 and the number of carbon atoms in the alkyl group is less than 12, a good peak may not be obtained. In addition, in polyoxyethylene alkyl ethers in which the average number of moles of oxyethylene groups added is more than 20 and the number of carbon atoms in the alkyl group is more than 17, a good peak may not be obtained or carryover may occur.

[0073] From the viewpoint of increasing the solubility of the surfactant, achieving good hemolysis, and measuring hemoglobin with high accuracy, the average number of moles of oxyethylene groups added in component A1 is preferably 9 or more, more preferably 10 or more, even more preferably 11 or more, and preferably 19 or less.

[0074] From the viewpoint of effectively exerting the effects of the present invention and enhancing the storage stability of a mixed liquid in which a hemoglobin measuring reagent and a test substance are mixed, the number of carbon atoms in the alkyl group of component A1 is preferably 17 or less, more preferably 16 or less, and particularly preferably 12 or 16. When the alkyl group has 12 carbon atoms, component A1 is polyoxyethylene lauryl ether, and when the alkyl group has 16 carbon atoms, component A1 is polyoxyethylene cetyl ether.

[0075] Therefore, it is particularly preferable that component A1 is polyoxyethylene lauryl ether having an average number of moles of oxyethylene groups added of 8 or more and 20 or less, or polyoxyethylene cetyl ether having an average number of moles of oxyethylene groups added of 8 or more and 20 or less.

[0076] When component A1 is polyoxyethylene lauryl ether, the average number of moles of oxyethylene groups added in the polyoxyethylene lauryl ether is preferably 9 or more, more preferably 10 or more, even more preferably 11 or more, and preferably 19 or less, more preferably 16 or less, and even more preferably 13 or less. The average number of moles of oxyethylene groups added in the polyoxyethylene lauryl ether is also preferably 9, 12 or 19, and most preferably 12. When the average number of moles of oxyethylene groups added is in the above-mentioned preferred range or value, the solubility of the surfactant can be further increased, hemolysis can be performed satisfactorily, hemoglobins can be measured with higher accuracy, and the storage stability of a mixture obtained by mixing a hemoglobin measuring reagent and a test substance can be further increased.

[0077] When component A1 is polyoxyethylene cetyl ether, the average number of moles of oxyethylene groups added in the polyoxyethylene cetyl ether is preferably 10 or more, more preferably 12 or more, preferably 19 or less, more preferably 16 or less, and even more preferably 14 or less. The average number of moles of oxyethylene groups added in the polyoxyethylene cetyl ether is also preferably 13 or 20, and most preferably 13. When the average number of moles of oxyethylene groups added is in the above-mentioned preferred range or value, the solubility of the surfactant can be further increased, hemolysis can be performed satisfactorily, hemoglobins can be measured with higher accuracy, and the storage stability of a mixture obtained by mixing a hemoglobin measuring reagent and a test substance can be further increased.

[0078] Therefore, Component A1 is preferably polyoxyethylene lauryl ether having an average number of moles of oxyethylene groups added of 9, 12 or 19, or polyoxyethylene cetyl ether having an average number of moles of oxyethylene groups added of 13 or 20. Moreover, Component A1 is most preferably polyoxyethylene lauryl ether having an average number of moles of oxyethylene groups added of 12, or polyoxyethylene cetyl ether having an average number of moles of oxyethylene groups added of 13.

[0079] From the viewpoint of effectively exerting the effects of the present invention, and from the viewpoint of enhancing the storage stability of the hemoglobin measuring reagent and the storage stability of a mixed liquid in which the reagent is mixed with a test substance, component A1 is preferably a polyoxyethylene alkyl ether in which the average number of moles of oxyethylene groups added is from 10 to 15 and the number of carbon atoms in the alkyl group is from 12 to 17. That is, component A1 is preferably component A1'.

[0080] The HLB (Hydrophilic Lipophilic Balance) value of component A1 is preferably 10 or more, more preferably 12 or more, and preferably 18 or less, more preferably 16 or less. When the HLB value is equal to or more than the lower limit, the generation of micelles can be suppressed, and clogging of the column can be effectively suppressed. When the HLB value is equal to or less than the upper limit, the cell membrane of the blood cell component can be sufficiently dissolved, and clogging of the column can be effectively suppressed.

[0081] The HLB value of component A1 and the HLB values ​​of each component described later are HLB values ​​according to the Griffin method. The HLB value is a value between 0 and 20, and the smaller the HLB value, the stronger the hydrophobicity (lipophilicity), and the larger the HLB value, the stronger the hydrophilicity. The HLB value according to the Griffin method is calculated according to the following formula.

[0082] HLB value = 20 x (molecular weight of hydrophilic group / molecular weight)

[0083] The cloud point of component A1 is preferably 80° C. or higher, more preferably 90° C. or higher, and preferably 150° C. or lower, more preferably 120° C. or lower. When the cloud point is equal to or higher than the lower limit and equal to or lower than the upper limit, the solubility of the surfactant can be increased, and a reagent for measuring hemoglobins can be successfully prepared.

[0084] The cloud point is the temperature at which a transparent or translucent liquid undergoes phase separation due to a change in temperature, resulting in the liquid becoming opaque. The cloud point is also commonly referred to as the lower critical solution temperature.

[0085] The content of component A1 in 100% by weight of the hemoglobin measuring reagent is preferably 0.01% by weight or more, more preferably 0.05% by weight or more, even more preferably 0.08% by weight or more, and particularly preferably 0.1% by weight or more. The content of component A1 in 100% by weight of the hemoglobin measuring reagent is preferably 1.0% by weight or less, more preferably 0.8% by weight or less, even more preferably 0.6% by weight or less, and particularly preferably 0.5% by weight or less. When the content of component A1 is equal to or more than the above lower limit and equal to or less than the above upper limit, the effects of the present invention can be more effectively exhibited, and the storage stability of the mixture in which the hemoglobin measuring reagent and the test substance are mixed can be further improved.

[0086] Commercially available products of component A1 include Kao Corporation's "Emulgen 109P" (polyoxyethylene lauryl ether having an average number of added moles of oxyethylene groups of 9, polyoxyethylene (9) lauryl ether), Kao Corporation's "Emulgen 120" (polyoxyethylene lauryl ether having an average number of added moles of oxyethylene groups of 12, polyoxyethylene (12) lauryl ether), Kao Corporation's "Emulgen 147" (polyoxyethylene lauryl ether having an average number of added moles of oxyethylene groups of 19, polyoxyethylene (19) lauryl ether), Kao Corporation's "Emulgen 220" (polyoxyethylene cetyl ether having an average number of added moles of oxyethylene groups of 13, polyoxyethylene (13) cetyl ether), and Sigma-Aldrich's "Brij (registered trademark) 58" (polyoxyethylene cetyl ether having an average number of added moles of oxyethylene groups of 20, polyoxyethylene (20) cetyl ether).

[0087] <Ingredient A2> Component A2 is a polyoxyethylene stearyl ether having an average number of moles of oxyethylene groups added of 40 or more and 60 or less. Component A2 is a component represented by the following formula (2). Only one type of component A2 may be used, or two or more types may be used in combination.

[0088] C 18 H 37 O(CH2CH2O)n H (2)

[0089] In the above formula (2), n represents a number of 40 or more and 60 or less.

[0090] In polyoxyethylene stearyl ether having an average number of moles of oxyethylene groups added of less than 40, the surfactant is difficult to dissolve, and a hemoglobin measuring reagent may not be prepared. In addition, in polyoxyethylene stearyl ether having an average number of moles of oxyethylene groups added of less than 40, a good peak may not be obtained. In addition, in polyoxyethylene stearyl ether having an average number of moles of oxyethylene groups added of more than 60, a good peak may not be obtained or carryover may occur.

[0091] From the viewpoint of increasing the solubility of the surfactant, and from the viewpoint of achieving good hemolysis and high-precision measurement of hemoglobins, the average number of moles of oxyethylene groups added in component A2 is preferably not less than 45 and preferably not more than 55. From the viewpoint of further increasing the solubility of the surfactant, and from the viewpoint of achieving good hemolysis and high-precision measurement of hemoglobins, the average number of moles of oxyethylene groups added in component A2 is most preferably 50.

[0092] The HLB value of component A2 is preferably 13 or more, more preferably 15 or more, and preferably 19 or less, more preferably 18 or less. When the HLB value is equal to or greater than the lower limit, the generation of micelles can be suppressed, and clogging of the column can be effectively suppressed. When the HLB value is equal to or less than the upper limit, the cell membrane of the blood cell component can be sufficiently dissolved, and clogging of the column can be effectively suppressed.

[0093] The HLB value of component A2 can be determined by the method described above.

[0094] The cloud point of component A2 is preferably 80° C. or higher, more preferably 90° C. or higher. When the cloud point is equal to or higher than the lower limit, the solubility of the surfactant can be increased, and a reagent for measuring hemoglobins can be successfully prepared.

[0095] The content of component A2 in 100% by weight of the hemoglobin measuring reagent is preferably 0.01% by weight or more, more preferably 0.05% by weight or more, even more preferably 0.08% by weight or more, and particularly preferably 0.1% by weight or more. The content of component A2 in 100% by weight of the hemoglobin measuring reagent is preferably 1.0% by weight or less, more preferably 0.8% by weight or less, even more preferably 0.6% by weight or less, and particularly preferably 0.5% by weight or less. When the content of component A2 is equal to or more than the lower limit and equal to or less than the upper limit, the effects of the present invention can be more effectively exhibited.

[0096] Commercially available products of component A2 include "EMULGEN 350" manufactured by Kao Corporation (polyoxyethylene stearyl ether having an average added mole number of oxyethylene groups of 50, polyoxyethylene (50) stearyl ether).

[0097] <Ingredient A3> Component A3 is a polyoxyethylene oleyl ether having an average number of moles of oxyethylene groups added of 9 to 15. Component A3 is a component represented by the following formula (3). Only one type of component A3 may be used, or two or more types may be used in combination.

[0098] C 18 H 35 O(CH2CH2O) n H (3)

[0099] In the above formula (3), n represents a number of 9 or more and 15 or less.

[0100] In polyoxyethylene oleyl ether having an average number of moles of oxyethylene groups added of less than 9, the surfactant is difficult to dissolve, and a hemoglobin measuring reagent may not be prepared. In addition, in polyoxyethylene oleyl ether having an average number of moles of oxyethylene groups added of less than 9, a good peak may not be obtained. In addition, in polyoxyethylene oleyl ether having an average number of moles of oxyethylene groups added of more than 15, a good peak may not be obtained or carryover may occur.

[0101] From the viewpoint of increasing the solubility of the surfactant and achieving good hemolysis and high-precision measurement of hemoglobins, the average number of moles of oxyethylene groups added in component A3 is preferably not more than 14. From the viewpoint of further increasing the solubility of the surfactant and achieving good hemolysis and high-precision measurement of hemoglobins, the average number of moles of oxyethylene groups added in component A3 is particularly preferably 9 or 13, and most preferably 13.

[0102] From the viewpoint of effectively exerting the effects of the present invention and enhancing the storage stability of the hemoglobin measuring reagent and the storage stability of a mixed solution obtained by mixing the reagent with a test substance, component A3 is preferably polyoxyethylene oleyl ether having an average added mole number of oxyethylene groups of 10 or more and 15 or less. That is, component A3 is preferably component A3'.

[0103] The HLB value of component A3 is preferably 10 or more, more preferably 12 or more, preferably 17 or less, more preferably 15 or less. When the HLB value is equal to or greater than the lower limit, the generation of micelles can be suppressed, and clogging of the column can be effectively suppressed. When the HLB value is equal to or less than the upper limit, the cell membrane of the blood cell component can be sufficiently dissolved, and clogging of the column can be effectively suppressed.

[0104] The HLB value of component A3 can be determined by the method described above.

[0105] The cloud point of component A3 is preferably 50° C. or higher, more preferably 85° C. or higher, and preferably 100° C. or lower, more preferably 95° C. or lower. When the cloud point is equal to or higher than the lower limit and equal to or lower than the upper limit, the solubility of the surfactant can be increased, and a reagent for measuring hemoglobins can be successfully prepared.

[0106] The content of component A3 in 100% by weight of the hemoglobin measuring reagent is preferably 0.01% by weight or more, more preferably 0.05% by weight or more, even more preferably 0.08% by weight or more, and particularly preferably 0.1% by weight or more. The content of component A3 in 100% by weight of the hemoglobin measuring reagent is preferably 1.0% by weight or less, more preferably 0.8% by weight or less, even more preferably 0.6% by weight or less, and particularly preferably 0.5% by weight or less. When the content of component A3 is equal to or more than the lower limit and equal to or less than the upper limit, the effects of the present invention can be more effectively exhibited.

[0107] Commercially available products of component A3 include Kao Corporation's "EMULGEN 409PV" (polyoxyethylene oleyl ether with an average number of moles of oxyethylene groups added of 9, polyoxyethylene (9) oleyl ether) and Kao Corporation's "EMULGEN 420" (polyoxyethylene oleyl ether with an average number of moles of oxyethylene groups added of 13, polyoxyethylene (13) oleyl ether).

[0108] <Ingredient A4> Component A4 is a polyoxyethylene-sec-alkyl ether in which the average number of moles of oxyethylene groups added is 6 or more and 10 or less, and the number of carbon atoms in the alkyl group is 11 or more and 15 or less. Component A4 is a component represented by the following formula (4). Component A4 is an ethylene oxide adduct of a secondary alcohol having a carbon number of 11 or more and 15 or less. Component A4 is different from Component A1. Only one type of Component A4 may be used, or two or more types may be used in combination.

[0109] C m H 2m+1 O(CH2CH2O) n H (4)

[0110] In the above formula (4), m represents a number of 11 or more and 15 or less, and n represents a number of 6 or more and 10 or less.

[0111] In polyoxyethylene-sec-alkyl ethers in which the average number of moles of oxyethylene groups added is less than 6 and the number of carbon atoms in the alkyl group is from 11 to 15, the surfactant is difficult to dissolve, and a reagent for measuring hemoglobins may not be prepared. In addition, in polyoxyethylene-sec-alkyl ethers in which the average number of moles of oxyethylene groups added is less than 6 and the number of carbon atoms in the alkyl group is from 11 to 15, a good peak may not be obtained.

[0112] From the viewpoint of increasing the solubility of the surfactant and achieving good hemolysis and high-precision measurement of hemoglobins, the average number of moles of oxyethylene groups added in component A4 is preferably 7 or more and preferably 9 or less, and more preferably 7 or 9.

[0113] The HLB value of component A4 is preferably 10 or more, more preferably 12 or more, and preferably 17 or less, more preferably 15 or less. When the HLB value is equal to or greater than the lower limit, the generation of micelles can be suppressed, and clogging of the column can be effectively suppressed. When the HLB value is equal to or less than the upper limit, the cell membrane of the blood cell component can be sufficiently dissolved, and clogging of the column can be effectively suppressed.

[0114] The HLB value of component A4 can be determined by the method described above.

[0115] The cloud point of component A4 is preferably 30° C. or higher, and preferably 60° C. or lower. When the cloud point is equal to or higher than the lower limit and equal to or lower than the upper limit, the solubility of the surfactant can be increased, and a reagent for measuring hemoglobins can be successfully prepared.

[0116] The content of component A4 in 100% by weight of the hemoglobin measuring reagent is preferably 0.01% by weight or more, more preferably 0.05% by weight or more, even more preferably 0.08% by weight or more, and particularly preferably 0.1% by weight or more. The content of component A4 in 100% by weight of the hemoglobin measuring reagent is preferably 1.0% by weight or less, more preferably 0.8% by weight or less, even more preferably 0.6% by weight or less, and particularly preferably 0.5% by weight or less. When the content of component A4 is equal to or more than the lower limit and equal to or less than the upper limit, the effects of the present invention can be more effectively exhibited.

[0117] Commercially available products of component A4 include Kao Corporation's "Emulgen 707" (a polyoxyethylene-sec-alkyl ether having an average added mole number of oxyethylene groups of 7 and an alkyl group having 11 to 15 carbon atoms) and Kao Corporation's "Emulgen 709" (a polyoxyethylene-sec-alkyl ether having an average added mole number of oxyethylene groups of 9 and an alkyl group having 11 to 15 carbon atoms).

[0118] <Ingredient A5> Component A5 is polyoxyethylene tridecyl ether having an average number of moles of oxyethylene groups added of 15. Component A5 is a component represented by the following formula (5). Only one type of component A5 may be used, or two or more types may be used in combination.

[0119] C 13 H 27 O(CH2CH2O) 15 H (5)

[0120] The content of component A5 in 100% by weight of the hemoglobin measuring reagent is preferably 0.01% by weight or more, more preferably 0.05% by weight or more, even more preferably 0.08% by weight or more, and particularly preferably 0.1% by weight or more. The content of component A5 in 100% by weight of the hemoglobin measuring reagent is preferably 1.0% by weight or less, more preferably 0.8% by weight or less, even more preferably 0.6% by weight or less, and particularly preferably 0.5% by weight or less. When the content of component A5 is equal to or more than the lower limit and equal to or less than the upper limit, the effects of the present invention can be more effectively exhibited.

[0121] Commercially available products of component A5 include "Leocol TD-150" manufactured by Lion Corporation.

[0122] <Ingredient A6> Component A6 is a polyoxyethylene polyoxypropylene alkyl ether having an HLB value of 11 or more and 15 or less. The polyoxyethylene polyoxypropylene alkyl ether has an oxypropylene group and an oxyethylene group. Component A6 is a component represented by the following formula (6). Only one type of component A6 may be used, or two or more types may be used in combination.

[0123] R-(CH2CH(CH3)O) m (CH2CH2O) n H (6)

[0124] In the above formula (6), R represents an alkyl group, m represents a number of 1 or more, and n represents a number of 1 or more.

[0125] The HLB value of component A6 is preferably 11.5 or more, more preferably 12 or more, and preferably 14.5 or less. When the HLB value is equal to or more than the lower limit, the generation of micelles can be suppressed, and clogging of the column can be effectively suppressed. When the HLB value is equal to or less than the upper limit, the cell membrane of the blood cell component can be sufficiently dissolved, and clogging of the column can be effectively suppressed. From the viewpoint of more effectively exerting the effects of the present invention and more effectively suppressing clogging of the column, the HLB value of component A6 is preferably 12.5, 12.7, or 14.0.

[0126] The HLB value of component A6 can be determined by the method described above.

[0127] The cloud point of component A6 is preferably 30° C. or higher, more preferably 50° C. or higher, and preferably 95° C. or lower, more preferably 90° C. or lower. When the cloud point is equal to or higher than the lower limit and equal to or lower than the upper limit, the solubility of the surfactant can be increased, and a reagent for measuring hemoglobins can be successfully prepared.

[0128] The content of component A6 in 100% by weight of the hemoglobin measuring reagent is preferably 0.01% by weight or more, more preferably 0.05% by weight or more, even more preferably 0.08% by weight or more, and particularly preferably 0.1% by weight or more. The content of component A6 in 100% by weight of the hemoglobin measuring reagent is preferably 1.0% by weight or less, more preferably 0.8% by weight or less, even more preferably 0.6% by weight or less, and particularly preferably 0.5% by weight or less. When the content of component A6 is equal to or more than the lower limit and equal to or less than the upper limit, the effects of the present invention can be more effectively exhibited.

[0129] Commercially available products of component A6 include Kao Corporation's "EMULGEN LS-106" (a polyoxyethylene polyoxypropylene alkyl ether with an HLB value of 12.5), Kao Corporation's "EMULGEN LS-114" (a polyoxyethylene polyoxypropylene alkyl (C12-14) ether with an HLB value of 14.0), and Kao Corporation's "EMULGEN MS-110" (a polyoxyethylene polyoxypropylene alkyl ether with an HLB value of 12.7).

[0130] <Ingredient A7> Component A7 is n-nonanoyl-N-methyl-D-glucamine.

[0131] The content of component A7 in 100% by weight of the hemoglobin measuring reagent is preferably 0.01% by weight or more, more preferably 0.05% by weight or more, even more preferably 0.08% by weight or more, and particularly preferably 0.1% by weight or more. The content of component A7 in 100% by weight of the hemoglobin measuring reagent is preferably 1.0% by weight or less, more preferably 0.8% by weight or less, even more preferably 0.6% by weight or less, and particularly preferably 0.5% by weight or less. When the content of component A7 is equal to or more than the lower limit and equal to or less than the upper limit, the effects of the present invention can be more effectively exhibited.

[0132] Commercially available products of component A7 include "MEGA-9" manufactured by Dojindo Chemical Industries, Ltd.

[0133] <Ingredient A8> Component A8 is n-octyl-β-D-glucopyranoside.

[0134] The content of component A8 in 100% by weight of the hemoglobin measuring reagent is preferably 0.01% by weight or more, more preferably 0.05% by weight or more, even more preferably 0.08% by weight or more, and particularly preferably 0.1% by weight or more. The content of component A8 in 100% by weight of the hemoglobin measuring reagent is preferably 1.0% by weight or less, more preferably 0.8% by weight or less, even more preferably 0.6% by weight or less, and particularly preferably 0.5% by weight or less. When the content of component A8 is equal to or more than the lower limit and equal to or less than the upper limit, the effects of the present invention can be more effectively exhibited.

[0135] Commercially available products of component A8 include "n-octyl-β-D-glucopyranoside" manufactured by Dojindo Chemical Industries, Ltd.

[0136] <Ingredient A9> Component A9 is saponin. Only one type of component A9 may be used, or two or more types may be used in combination.

[0137] Component A9 is preferably soybean saponin, and more preferably soybean saponin represented by the following formula (9).

[0138] [ka]

[0139] The content of component A9 in 100% by weight of the hemoglobin measuring reagent is preferably 0.01% by weight or more, more preferably 0.05% by weight or more, even more preferably 0.08% by weight or more, and particularly preferably 0.1% by weight or more. The content of component A9 in 100% by weight of the hemoglobin measuring reagent is preferably 1.0% by weight or less, more preferably 0.8% by weight or less, even more preferably 0.6% by weight or less, and particularly preferably 0.5% by weight or less. When the content of component A9 is equal to or more than the lower limit and equal to or less than the upper limit, the effects of the present invention can be more effectively exhibited.

[0140] Commercially available products of component A9 include "Saponin" manufactured by Nacalai Tesque, Inc.

[0141] (Amphoteric surfactant) The hemoglobin measuring reagent preferably contains an amphoteric surfactant. The surfactant is any one of components B1 to B3. The amphoteric surfactant may be used alone or in combination of two or more of components B1 to B3.

[0142] <Ingredient B1> Component B1 is 3-[(3-cholamidopropyl)dimethylammonio]propanesulfonate (CHAPS).

[0143] The content of component B1 in the above hemoglobin measuring reagent (100% by weight) is preferably 0.01% by weight or more, more preferably 0.05% by weight or more, even more preferably 0.08% by weight or more, and particularly preferably 0.1% by weight or more. The content of component B1 in the above hemoglobin measuring reagent (100% by weight) is preferably 1.0% by weight or less, more preferably 0.8% by weight or less, even more preferably 0.6% by weight or less, and particularly preferably 0.5% by weight or less. When the content of component B1 is equal to or more than the above lower limit and equal to or less than the above upper limit, the effects of the present invention can be more effectively exhibited.

[0144] Commercially available products of component B1 include "CHAPS" manufactured by Dojindo Chemical Industries, Ltd.

[0145] <Ingredient B2> Component B2 is 3-[(3-cholamidopropyl)dimethylammonio]-2-hydroxypropanesulfonate (CHAPSO).

[0146] The content of component B2 in 100% by weight of the hemoglobin measuring reagent is preferably 0.01% by weight or more, more preferably 0.05% by weight or more, even more preferably 0.08% by weight or more, and particularly preferably 0.1% by weight or more. The content of component B2 in 100% by weight of the hemoglobin measuring reagent is preferably 1.0% by weight or less, more preferably 0.8% by weight or less, even more preferably 0.6% by weight or less, and particularly preferably 0.5% by weight or less. When the content of component B2 is equal to or more than the lower limit and equal to or less than the upper limit, the effects of the present invention can be more effectively exhibited.

[0147] Commercially available products of component B2 include "CHAPSO" manufactured by Dojindo Chemical Industries, Ltd.

[0148] <Ingredient B3> Component B3 is lauryl dimethylamine oxide.

[0149] The content of component B3 in the above hemoglobin measuring reagent (100% by weight) is preferably 0.01% by weight or more, more preferably 0.05% by weight or more, even more preferably 0.08% by weight or more, and particularly preferably 0.1% by weight or more. The content of component B3 in the above hemoglobin measuring reagent (100% by weight) is preferably 1.0% by weight or less, more preferably 0.8% by weight or less, even more preferably 0.6% by weight or less, and particularly preferably 0.5% by weight or less. When the content of component B3 is equal to or more than the above lower limit and equal to or less than the above upper limit, the effects of the present invention can be more effectively exhibited.

[0150] Commercially available products of component B3 include "Amphitol 20N" manufactured by Kao Corporation.

[0151] (Buffer) The hemoglobin measuring reagent preferably contains a buffer. By containing the buffer, the pH fluctuation can be suppressed. The buffer may be used alone or in combination of two or more.

[0152] Examples of the buffer include phosphates such as sodium phosphate, disodium hydrogen phosphate, sodium dihydrogen phosphate, potassium phosphate, dipotassium hydrogen phosphate, and potassium dihydrogen phosphate, carbonates such as sodium carbonate and sodium hydrogen carbonate, borates such as sodium borate, carboxylic acids, dicarboxylic acids, carboxylic acid derivatives, hydroxycarboxylic acids, aniline, aniline derivatives, amino acids, amine compounds, imidazole compounds, alcohol compounds, ethylenediaminetetraacetic acid, pyrophosphoric acid, pyridine, cacodylic acid, glycerol phosphate, 2,4,6-collidine, N-ethylmorpholine, morpholine, 4-aminopyridine, ammonia, ephedrine, hydroxyproline, piperidine, tris(hydroxymethyl)aminomethane, and glycylglycine.

[0153] From the viewpoint of maintaining the pH of the above-mentioned hemoglobin measuring reagent within a preferred range described below, the above-mentioned buffering agent is preferably a phosphate.

[0154] The content of the buffering agent in the hemoglobin measuring reagent is not particularly limited as long as it is a content that can exhibit a buffering effect. The content of the buffering agent in 100% by weight of the hemoglobin measuring reagent may be 0.01% by weight or more, 0.02% by weight or more, 0.2% by weight or less, or 0.1% by weight or less.

[0155] (Inorganic salts) The hemoglobin measuring reagent preferably contains an inorganic salt. By containing the inorganic salt, the osmotic pressure can be well adjusted. The inorganic salt may be used alone or in combination of two or more kinds.

[0156] Examples of the inorganic salts include sodium chloride, potassium chloride, sodium sulfate, and potassium sulfate.

[0157] From the viewpoint of maintaining the osmotic pressure of the hemoglobin measuring reagent within the preferred range described below, the inorganic salt is preferably sodium chloride, potassium chloride, sodium sulfate, or potassium sulfate, and more preferably sodium chloride.

[0158] The content of the inorganic salts in the hemoglobin measuring reagent is not particularly limited. The content of the inorganic salts in 100% by weight of the hemoglobin measuring reagent may be 0.1% by weight or more, or 1.0% by weight or less.

[0159] (water) The above-mentioned hemoglobin measuring reagent preferably contains water.

[0160] The content of the water in 100% by weight of the reagent for measuring hemoglobins is preferably 80% by weight or more, more preferably 90% by weight or more, and even more preferably 95% by weight or more.

[0161] (Other Ingredients) The hemoglobin measuring reagent may contain other components in addition to the above-mentioned components. The other components include a preservative, a hemoglobin stabilizer, a pH adjuster, etc. Each of the other components may be used alone or in combination of two or more.

[0162] Such preservatives include sodium azide, thymol, and sodium propionate.

[0163] Examples of the hemoglobin stabilizer include chelating agents such as ethylenediaminetetraacetic acid (EDTA), and glutathione.

[0164] The pH adjuster includes acids such as hydrochloric acid, phosphoric acid, nitric acid, and sulfuric acid, and bases such as sodium hydroxide, potassium hydroxide, lithium hydroxide, magnesium hydroxide, barium hydroxide, and calcium hydroxide.

[0165] (Other details of hemoglobin measurement reagents) The hemoglobin measuring reagent preferably contains the nonionic surfactant, more preferably contains component A1, component A2, component A3, component A4, component A5 or component A6 as the nonionic surfactant, further preferably contains component A1 or component A3, and particularly preferably contains component A1' or component A3'. In this case, the effect of the present invention can be more effectively exhibited. In addition, the storage stability of the mixture in which the hemoglobin measuring reagent and the test substance are mixed can be further improved.

[0166] When the hemoglobin measuring reagent contains the nonionic surfactant, the content of the nonionic surfactant (total content of components A1 to A9) in 100% by weight of the hemoglobin measuring reagent is preferably 0.01% by weight or more, more preferably 0.05% by weight or more, even more preferably 0.08% by weight or more, and particularly preferably 0.1% by weight or more. In 100% by weight of the hemoglobin measuring reagent, the content of the nonionic surfactant (total content of components A1 to A9) is preferably 1.0% by weight or less, more preferably 0.8% by weight or less, even more preferably 0.6% by weight or less, and particularly preferably 0.5% by weight or less. When the content of the nonionic surfactant (total content of components A1 to A9) is the above lower limit or more and the above upper limit or less, the effects of the present invention can be more effectively exhibited. In addition, the storage stability of the mixture in which the hemoglobin measuring reagent and the test substance are mixed can be further improved.

[0167] When the hemoglobin measuring reagent contains the amphoteric surfactant, the content of the amphoteric surfactant (the total content of components B1 to B3) in 100% by weight of the hemoglobin measuring reagent is preferably 0.01% by weight or more, more preferably 0.05% by weight or more, even more preferably 0.08% by weight or more, and particularly preferably 0.1% by weight or more. In 100% by weight of the hemoglobin measuring reagent, the content of the amphoteric surfactant (the total content of components B1 to B3) is preferably 1.0% by weight or less, more preferably 0.8% by weight or less, even more preferably 0.6% by weight or less, and particularly preferably 0.5% by weight or less. When the content of the amphoteric surfactant (the total content of components B1 to B3) is the above lower limit or more and the above upper limit or less, the effects of the present invention can be more effectively exhibited.

[0168] The hemoglobin measuring reagent preferably does not contain component X. In the present invention, the effects of the present invention can be achieved even without component X. Furthermore, in the present invention, the storage stability of a mixed liquid in which the hemoglobin measuring reagent and a test substance are mixed can be improved even without component X. However, the hemoglobin measuring reagent may contain component X. For example, the hemoglobin measuring reagent may contain component X at a concentration that is not subject to REACH regulations (content of component X is less than 0.1% by weight in 100% by weight of the hemoglobin measuring reagent).

[0169] The pH of the hemoglobin measuring reagent is preferably 6.0 or more, more preferably 7.0 or more, and preferably 8.5 or less, more preferably 8.0 or less. When the pH is equal to or more than the lower limit and equal to or less than the upper limit, hemolysis can be achieved more satisfactorily.

[0170] The osmotic pressure of the hemoglobin measuring reagent is preferably 50 mOsm or more, more preferably 75 mOsm or more, and preferably 200 mOsm or less, more preferably 150 mOsm or less. When the osmotic pressure is equal to or more than the lower limit and equal to or less than the upper limit, hemolysis can be more effectively achieved.

[0171] The osmotic pressure can be measured using an osmometer (for example, "Osmometer 3250" manufactured by Advanced Instruments).

[0172] The above-mentioned reagent for measuring hemoglobins is suitably used for hemolyzing red blood cells. The above-mentioned reagent for measuring hemoglobins is preferably a hemolysis reagent.

[0173] The hemoglobin measuring reagent is preferably used by mixing with a test substance, which may be a red blood cell-containing sample such as blood, a hemoglobin standard substance, or a hemoglobin substance for measurement control.

[0174] The hemoglobin measuring reagent is preferably used as a diluent for dissolving or diluting a specimen that does not contain red blood cells and has a known hemoglobin concentration (hemoglobin standard substance, hemoglobin substance for measurement control, etc.) Furthermore, the hemoglobin measuring reagent is preferably used as a washing solution and a column washing solution for a liquid chromatograph.

[0175] (Method of measuring hemoglobin) The method for measuring hemoglobins according to the present invention includes the steps of: mixing a red blood cell-containing sample with the above-mentioned hemoglobin measuring reagent to obtain a mixed solution; and measuring the mixed solution by cation exchange liquid chromatography.

[0176] The cation exchange liquid chromatography is preferably cation exchange high performance liquid chromatography.

[0177] The red blood cell-containing sample may be blood or the like.

[0178] In general, in the above-mentioned cation exchange liquid chromatography, in addition to a mixture prepared from blood (sample containing red blood cells) collected from a patient or the like, a mixture prepared from a sample that does not contain red blood cells and has a known concentration of hemoglobins to be measured is also measured. Examples of the above-mentioned sample that does not contain red blood cells and has a known concentration of hemoglobins to be measured include a hemoglobin standard substance to be measured (hemoglobins of known concentration to be measured) and a hemoglobin substance for measurement control to be measured (hemoglobins of known concentration to be measured, preferably measuring multiple concentrations such as low concentration, medium concentration, and high concentration). The above-mentioned hemoglobin standard substance and the above-mentioned hemoglobin substance for measurement control are preferably samples prepared at the time of use, freeze-dried samples, or frozen samples. The above-mentioned hemoglobin standard substance and the above-mentioned hemoglobin substance for measurement control are commercially available as freeze-dried or frozen products.

[0179] In the above hemoglobin measuring method, it is preferable to obtain the concentration of hemoglobin as follows, for example. (1) The above red blood cell-containing specimen and the above hemoglobin measuring reagent are mixed to obtain a mixed solution. (2) The above mixed solution is measured by cation exchange liquid chromatography. (3) The ratio of the peak area of ​​the hemoglobin to be measured to the total peak area of ​​hemoglobin (peak area of ​​the hemoglobin to be measured / total peak area of ​​hemoglobin) is set as the hemoglobin value (concentration of hemoglobin) of the measurement target. For example, when the hemoglobin A1c value is obtained, the ratio of the peak area of ​​hemoglobin A1c to the total peak area of ​​hemoglobin (peak area of ​​hemoglobin A1c / total peak area of ​​hemoglobin) in the above (3) is set as the hemoglobin A1c value.

[0180] In the above hemoglobin measuring method, the concentration of hemoglobin can be obtained, for example, as follows: (1) The red blood cell-containing specimen is mixed with the hemoglobin measuring reagent to obtain a first mixed liquid. (2) A hemoglobin-containing specimen having a known concentration of hemoglobin to be measured is mixed with the hemoglobin measuring reagent to obtain a second mixed liquid. (3) The first mixed liquid and the second mixed liquid are measured by cation exchange liquid chromatography. (4) The measurement value obtained by measuring the mixed liquid containing the hemoglobin-containing specimen having a known concentration of hemoglobin to be measured by cation exchange liquid chromatography is compared with the measurement value obtained by measuring the mixed liquid containing the red blood cell-containing specimen by cation exchange liquid chromatography to determine the concentration of hemoglobin in the red blood cell-containing specimen.

[0181] From the viewpoint of achieving even better hemolysis, it is preferable to mix the hemoglobin measurement reagent in an amount of preferably 25 mL or more, more preferably 50 mL or more, preferably 400 mL or less, more preferably 200 mL or less with 1 mL of the red blood cell-containing sample.

[0182] The cation exchange liquid chromatography is preferably performed using a salt gradient or a pH gradient, which may be a linear gradient or a step gradient.

[0183] In the measurement of the gradient, it is preferable to use two or more kinds of eluents. In the case of measurement with the gradient of the salt concentration, an eluent with a low salt concentration and an eluent with a high salt concentration (for example, an eluent with a NaCl concentration of 50 mM and an eluent with a NaCl concentration of 200 mM) can be used as the eluent. In the case of measurement with the pH gradient, two kinds of eluents with different pH (for example, an eluent with a pH of 5.4 and an eluent with a pH of 8.0) can be used. In addition, a commercially available product can be used as the eluent. Examples of the commercially available eluent include "Eluent 80A", "Eluent 80B", "Eluent 60A-VP / TP", "Eluent 60B-VP / TP", and "Eluent 60C-VP" manufactured by Arkray.

[0184] The cation exchange column used in the cation exchange liquid chromatography may be a conventionally known cation exchange column. The cation exchange column is preferably a column packed with a packing material having a cation exchange group such as a carboxyl group, a sulfonic acid group, or a phosphate group. Commercially available cation exchange columns include, for example, "Column Unit 80" and "Column Unit HSVI-VP" manufactured by Arkray.

[0185] The present invention will be specifically described below by way of examples, reference examples and comparative examples, but the present invention is not limited to the following examples.

[0186] (Examples 1 to 30, Reference Example A, and Comparative Examples 1 to 69) Preparation of hemoglobin measurement reagents: A first composition was obtained by mixing potassium dihydrogen phosphate, dipotassium hydrogen phosphate, sodium chloride, sodium azide, and water. A surfactant shown in Tables 2 to 6 was added to the obtained first composition and mixed to prepare a hemoglobin measuring reagent. The composition of the obtained hemoglobin measuring reagent is shown in Table 1 below. The type, content, HLB value, and cloud point of the surfactant in Table 1 are shown in Tables 2 to 6. The HLB value of the surfactant is a value measured by the above-mentioned method.

[0187] [Table 1]

[0188] (evaluation) (1) Solubility of surfactants The solubility of the surfactant when the surfactant was added to the first composition and mixed was visually confirmed. The solubility of the surfactant was evaluated according to the following criteria.

[0189] [Solubility criteria for surfactants] ○○: The surfactant dissolves completely in less than 15 minutes ○: The surfactant is completely dissolved in 15 to 30 minutes. △: The surfactant completely dissolves in 30 minutes or more but less than an hour. ×: The surfactant is completely dissolved in 1 hour or more, or is not dissolved at all.

[0190] (2) Measurement by cation exchange liquid chromatography Whole blood (red blood cell-containing specimen) contained in a blood collection tube (manufactured by Sekisui Medical Co., Ltd.) was prepared. 1 mL of whole blood was mixed with 100 mL of the obtained hemoglobin measurement reagent to obtain a mixture. The obtained mixture was measured under the following conditions. Note that, for hemoglobin measurement reagents for which the judgment result of "(1) Solubility of surfactant" was x, measurement by cation exchange liquid chromatography was not performed.

[0191] Cation exchange chromatography conditions: HPLC device: Glycohemoglobin analyzer (ARKRAY "HA-8180") Cation exchange column: Column Unit 80 (Arklay) Eluent A: Eluent 80A (Arklay) Eluent B: Eluent 80B (Arklay)

[0192] The measurement was carried out using the measurement method installed in the HPLC device.

[0193] (2-1) Peak separation pattern The following i) to iii) were confirmed for the chromatogram obtained by measuring the mixed liquid. In Reference Example A, the chromatogram peak pattern shown in FIG. 2 was obtained. In the obtained chromatogram, the peak detected at about 19 seconds is the hemoglobin A1c peak, and the peak detected at about 40 seconds is the hemoglobin A0 peak.

[0194] i) Hemoglobin A1c peak separation The peak height of hemoglobin A1c obtained in Reference Example A was compared with the peak height of hemoglobin A1c obtained in Examples and Comparative Examples. When the peak height of hemoglobin A1c obtained was not lower than the peak height of hemoglobin A1c obtained in Reference Example A by 50 or more in terms of absorbance standard, the separation of the hemoglobin A1c peak was judged to be good, and when it was lower than 50, it was judged to be poor.

[0195] ii) Hemoglobin A0 peak shape In Reference Example A, no peak was detected in the tail of the hemoglobin A0 peak. The shape of the tail of the hemoglobin A0 peak obtained in the Examples and Comparative Examples was confirmed. When no peak was detected in the tail of the peak, the shape of the hemoglobin A0 peak was judged to be good, and when a peak was detected, it was judged to be bad.

[0196] An example of a chromatogram judged to be good is shown in FIG. 3(a), and an example of a chromatogram judged to be bad is shown in FIG. 3(b).

[0197] iii) Peak shape of the first fraction In Reference Example A, no shoulder peak was detected in the peak of the first fraction. The peak shapes of the first fractions obtained in the Examples and Comparative Examples were confirmed. When no shoulder peak was detected in the peak of the first fraction, the peak shape of the first fraction was judged to be good, and when a shoulder peak was detected, it was judged to be poor.

[0198] An example of a chromatogram judged to be good is shown in Figure 4(a), and an example of a chromatogram judged to be bad is shown in Figure 4(b). The peak indicated by the arrow in Figure 4(b) is a shoulder peak.

[0199] [Criteria for peak separation pattern] ○: i) to iii) are all good. ×: Any of the following criteria i) to iii) is not acceptable

[0200] (2-2) Carryover After measuring the mixture of whole blood and the hemoglobin measuring reagent, the hemoglobin measuring reagent alone was measured five times in succession. The following i) to iii) were confirmed for the obtained chromatogram.

[0201] i) Hemoglobin A0 peak height In the first measurement of the hemoglobin measuring reagent, the peak height of hemoglobin A0 obtained in Reference Example A was compared with the peak height of hemoglobin A0 obtained in the Examples and Comparative Examples. When the peak height of hemoglobin A0 obtained was not increased by 100 or more based on absorbance compared to the peak height of hemoglobin A0 obtained in Reference Example A, it was judged as good, and when it increased by more than 100, it was judged as poor.

[0202] An example of a chromatogram obtained in Reference Example A is shown in Figure 5(a), an example of a chromatogram judged to be good is shown in Figure 5(b), and an example of a chromatogram judged to be poor is shown in Figure 5(c).

[0203] ii) Presence or absence of hemoglobin A1c peak In the first measurement of the hemoglobin measuring reagent, the presence or absence of a hemoglobin A1c peak was confirmed. If a hemoglobin A1c peak was not observed, it was judged as good, and if a hemoglobin A1c peak was observed, it was judged as poor.

[0204] iii) Presence or absence of drift In the first measurement of the hemoglobin measuring reagent, the presence or absence of drift of the hemoglobin A0 peak was confirmed. If no drift was observed, it was judged as good, and if drift was observed, it was judged as poor.

[0205] [Criteria for determining carryover] ○: i) to iii) are all good. ×: Any of the following criteria i) to iii) is not acceptable

[0206] (3) pH The pH of the hemoglobin measuring reagents obtained in Reference Example A and the Examples was measured using a pH meter ("F-52" manufactured by Horiba, Ltd.).

[0207] (4) Osmotic pressure The osmotic pressure of the hemoglobin measuring reagents obtained in Reference Example A and the Examples was measured using an osmometer (Advanced Instruments' "Osmometer 3250").

[0208] The compositions and results are shown in the following Tables 2 to 6. In Tables 2, 3, and 5, the value represented by "EO" means the average number of moles of oxyethylene groups added.

[0209] [Table 2]

[0210] [Table 3]

[0211] [Table 4]

[0212] [Table 5]

[0213] [Table 6]

[0214] It can be seen that the hemoglobin measuring reagents obtained in Examples 1 to 30 enable good hemolysis and enable high-precision measurement of hemoglobin.

[0215] (Reference Example A and Examples 31 to 38) A reagent for measuring hemoglobin was prepared in the same manner as in Example 1, except that the composition was changed as shown in Table 7.

[0216] (5) Storage stability of hemoglobin measurement reagents The hemoglobin measuring reagents obtained in Reference Example A and Examples 32, 34, and 36 to 38, in which the surfactant concentration was 0.5% by weight, were sealed in glass vials and stored for 7 days at 60° C. After storage, the properties of the hemoglobin measuring reagents were visually confirmed.

[0217] In general, hemoglobin measuring reagents are stored at room temperature. In this evaluation item, the hemoglobin measuring reagents are stored and evaluated under temperature conditions that are more severe than the normal storage conditions.

[0218] [Criteria for storage stability of hemoglobin measurement reagents (60℃, 7 days)] A: No phase separation occurs B: Phase separation occurs

[0219] (6) Storage stability of the mixture (6-1) Storage stability of mixture with whole blood Whole blood (sample containing red blood cells) was prepared. Also, the hemoglobin measuring reagents obtained in Reference Example A and Examples 31 to 36 were prepared. The whole blood was diluted 101 times with the hemoglobin measuring reagent to obtain a mixed solution. The obtained mixed solution was placed in a glass vial and stored at 4°C. Before storage, and on the 1st, 2nd, 5th, 7th, and 9th days after storage, the mixed solution was repeatedly measured three times under the measurement conditions described in "(2) Measurement by cation exchange liquid chromatography", and the hemoglobin A1c value and the change in the hemoglobin A1c value were calculated from the average values.

[0220] Hemoglobin A1c value (%) = hemoglobin A1c peak area / sum of hemoglobin peak areas

[0221] Change in hemoglobin A1c value (%) = hemoglobin A1c value before storage - hemoglobin A1c value after storage

[0222] Fig. 6(a) is a graph showing the relationship between the number of days stored and the hemoglobin A1c value in a mixture with whole blood, and Fig. 6(b) is a graph showing the relationship between the number of days stored and the amount of change in the hemoglobin A1c value in a mixture with whole blood.

[0223] [Criteria for mixture with whole blood] ○: The absolute difference between the change in hemoglobin A1c value on the 5th day and Reference Example A is 0.2% or less △: In the change in hemoglobin A1c value on the 5th day, the absolute value of the difference from Reference Example A is more than 0.2% and 0.4% or less. △△: In the change in hemoglobin A1c value on the 5th day, the absolute value of the difference from Reference Example A is more than 0.4% and 0.7% or less. ×: The absolute difference between the change in hemoglobin A1c value on the 5th day and Reference Example A exceeds 0.7%.

[0224] (6-2) Storage stability of the mixture with hemoglobin A1c substance (low concentration) (IRC-L) for measurement control A hemoglobin A1c substance (low concentration) (IRC-L) for measurement control with a hemoglobin A1c value of 5.8% was prepared. Also, the hemoglobin measurement reagents obtained in Reference Example A and Examples 31 to 36 were prepared. The hemoglobin A1c substance (low concentration) (IRC-L) for measurement control was diluted 101 times with the hemoglobin measurement reagent to obtain a mixed solution. The obtained mixed solution was placed in a glass vial and stored at 4°C. Before storage, and on the 1st, 2nd, 3rd, 9th, and 14th days after storage, the mixed solution was repeatedly measured three times under the measurement conditions in "(2) Measurement by cation exchange liquid chromatography", and the hemoglobin A1c value and the change in the hemoglobin A1c value were calculated from the average value in the same manner as above.

[0225] Fig. 7(a) is a diagram showing the relationship between the number of days stored and the hemoglobin A1c value in a mixture with a hemoglobin A1c substance (low concentration) (IRC-L) for measurement control. Fig. 7(b) is a diagram showing the relationship between the number of days stored and the amount of change in the hemoglobin A1c value in a mixture with a hemoglobin A1c substance (low concentration) (IRC-L) for measurement control.

[0226] [Criteria for storage stability of mixture with hemoglobin A1c substance (low concentration) (IRC-L) for measurement control] ○: The absolute difference between the change in hemoglobin A1c value on the 14th day and Reference Example A is 0.2% or less △: The absolute value of the difference from Reference Example A in the change in hemoglobin A1c value on the 14th day is more than 0.2% and 0.4% or less. △△: The absolute value of the difference from Reference Example A in the change in hemoglobin A1c value on the 14th day is more than 0.4% and 0.7% or less. ×: The absolute difference between the change in hemoglobin A1c value on the 14th day and Reference Example A exceeds 0.7%

[0227] (6-3) Storage stability of the mixture with hemoglobin A1c substance (high concentration) (IRC-H) for measurement and control Except for changing the hemoglobin A1c substance for measurement and control (low concentration) (IRC-L) to the hemoglobin A1c substance for measurement and control (high concentration) (IRC-H) with a hemoglobin A1c value of 10.4%, the hemoglobin A1c value and the change in hemoglobin A1c value were determined in the same manner as in "(6-2) Storage stability of the mixed solution with hemoglobin A1c substance for measurement and control (low concentration) (IRC-L)."

[0228] Fig. 8(a) is a diagram showing the relationship between the number of days stored and the hemoglobin A1c value in a mixture with a hemoglobin A1c substance (high concentration) (IRC-H) for measurement management. Fig. 8(b) is a diagram showing the relationship between the number of days stored and the amount of change in the hemoglobin A1c value in a mixture with a hemoglobin A1c substance (high concentration) (IRC-H) for measurement management.

[0229] [Criteria for storage stability of mixture with hemoglobin A1c substance (high concentration) (IRC-H) for measurement control] ○: The absolute difference between the change in hemoglobin A1c value on the 14th day and Reference Example A is 0.25% or less △: The absolute value of the difference from Reference Example A in the change in hemoglobin A1c value on the 14th day is more than 0.25% and 0.45% or less. △△: The absolute value of the difference from Reference Example A in the change in hemoglobin A1c value on the 14th day is more than 0.45% and 0.75% or less. ×: The absolute value of the difference from Reference Example A in the change in hemoglobin A1c value on the 14th day exceeds 0.75%

[0230] The compositions and results are shown in Table 7 below.

[0231] [Table 7]

[0232] The hemoglobin measuring reagents obtained in Examples 31 to 36 had improved storage stability compared to the hemoglobin measuring reagents obtained in Examples 37 and 38. Furthermore, the hemoglobin measuring reagents obtained in Examples 31 to 36 also had improved storage stability of a mixture obtained by mixing the reagent with a test substance. The hemoglobin measuring reagents obtained in Examples 31 to 36 can measure hemoglobin with high accuracy even after a mixture obtained by mixing the hemoglobin measuring reagent with a test substance is stored for a long period of time.

[0233] (7) Column durability Whole blood (red blood cell-containing sample), hemoglobin A1c substance (high concentration) (IRC-H) for measurement control with a hemoglobin A1c value of 10.4%, and the hemoglobin measurement reagent obtained in Reference Example A and Example 32 were prepared. The whole blood was diluted 101 times with the hemoglobin measurement reagent to obtain liquid (1). The hemoglobin A1c substance for measurement control was also diluted 101 times with the hemoglobin measurement reagent to obtain liquid (2). Liquid (1) is a measurement sample for applying a load to the column, and liquid (2) is a measurement sample for confirming the amount of change in the hemoglobin A1c value and the amount of change in the number of theoretical plates. The obtained liquids (1) and (2) were measured according to the following procedures and conditions.

[0234] First, the obtained liquid (2) was measured three times. Then, the obtained liquid (1) was passed through the column several times (several tens to 200 times), and the liquid (2) was measured three times each time. The liquids (1) and (2) were repeatedly measured according to the above procedure until the number of samples loaded on the column reached about 3000 samples.

[0235] Cation exchange chromatography conditions: HPLC device: Glycohemoglobin analyzer (ARKRAY "HA-8160VP") Cation exchange column: Column unit HSVI-VP (Arklay) Eluent A: Eluent 60A-VP / TP (Arklay) Eluent B: Eluent 60B-VP / TP (Arklay) Eluent C: Eluent 60C-VP (Arklay)

[0236] The measurement was carried out using the measurement method installed in the HPLC device.

[0237] 9(a) shows the relationship between the number of samples loaded onto the column and the amount of change in hemoglobin A1c value, and FIG. 9(b) shows the relationship between the number of samples loaded onto the column and the amount of change in theoretical plate number.

[0238] In FIG. 9(a), the vertical axis is the difference between the hemoglobin A1c value in the first measured liquid (2) and the hemoglobin A1c value in the liquid (2) measured with each number of loaded samples (hemoglobin A1c value in the first measured liquid (2) - hemoglobin A1c value in the liquid (2) measured with each number of loaded samples). In FIG. 9(b), the vertical axis is the difference between the number of theoretical plates in the first measured liquid (2) and the number of theoretical plates in the liquid (2) measured with each number of loaded samples (theoretical number of theoretical plates in the first measured liquid (2) - theoretical number of theoretical plates in the liquid (2) measured with each number of loaded samples).

[0239] The reagent for measuring hemoglobin obtained in Example 32 was superior to the reagent for measuring hemoglobin obtained in Reference Example A in terms of column durability.

Claims

1. A hemoglobin measuring reagent used for measuring hemoglobin by cation exchange liquid chromatography, comprising: Contains an amphoteric surfactant, A reagent for measuring hemoglobins, wherein the amphoteric surfactant is the following component B1, component B2 or component B3: Component B1: 3-[(3-cholamidopropyl)dimethylammonio]propanesulfonate Component B2: 3-[(3-cholamidopropyl)dimethylammonio]-2-hydroxypropanesulfonate Component B3: Lauryl dimethylamine oxide

2. A reagent for measuring hemoglobins as described in claim 1, wherein the content of the amphoteric surfactant is 0.01% by weight or more and 1.0% by weight or less.

3. A step of mixing a red blood cell-containing sample with the hemoglobin measuring reagent according to claim 1 or 2 to obtain a mixed solution; and measuring the mixture by cation exchange liquid chromatography.

Citation Information

Patent Citations

  • Method of separating hemoglobin a1c

    JP1983191968A

  • Measuring method of component in blood

    JP1989277755A

  • Method for separating and analyzing analysis body with electrostatic ion chromatography and method for separating and analyzing analysis body with fixed phase having double-charging feature for ion chromatography and multifunctional liquid chromatography

    JP1994229994A

  • Method and device for judging diabetes

    JP1995072132A

  • Cyanide-free reagents and methods for the determination of hemoglobin

    JP1997511575A